# Pirfenidone Use in Asbestosis Patients: Efficacy and Prognosis

> **NCT05133453** · NA · UNKNOWN · sponsor: **Cairo University** · enrollment: 40 (estimated)

## Conditions studied

- Asbestosis

## Interventions

- **DRUG:** Pirfenidone

## Key facts

- **NCT ID:** NCT05133453
- **Lead sponsor:** Cairo University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-02
- **Primary completion:** 2025-02
- **Final completion:** 2026-02
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05133453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05133453, "Pirfenidone Use in Asbestosis Patients: Efficacy and Prognosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05133453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*